Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "gene therapy" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 32
Tytuł:
Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
Autorzy:
Bargiel, J.B.
Cabaj, J.
Chmielewska, I.
Milanowski, J.
Powiązania:
https://bibliotekanauki.pl/articles/2098542.pdf
Data publikacji:
2021
Wydawca:
Instytut Medycyny Wsi
Tematy:
non-small cell lung cancer
crizotinib
therapy
gene rearrangement
tyrosine kinase inhibitor
patient
Opis:
Introduction. Currently, nearly 23,000 cases of lung cancer are diagnosed in Poland annually, of which 5% are cases with rearrangements in the ALK gene. In recent years, tremendous progress has been made in understanding the genetic makeup of this type of cancer, which has enabled the use of new therapies, in particular, molecularly targeted drugs. Crizotinib is the first oral small molecule inhibitor of ALK, MET and ROS1 receptor tyrosine Kinases approved by the European Medicines Agency(EMA). Case report. The paper presents the case of a 62-year-old patient diagnosed with non-small cell lung cancer with rearrangement in the ALK gene in stage IV of the disease. The patient was qualified for treatment with crizotinib under the B6 drug programme. Treatment started in May 2019. During treatment, assessment was made at 3 control points, where the first and second showed a partial response according to the RECIST 1.1 scale; in the next assessment, the response was maintained in the form of disease stabilization.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2021, 15, 3; 151-154
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Expression of genes modulated by epigallocatechin-3-gallate in breast cancer cells
Autorzy:
Bogacz, A.
Wolek, M.
Juskowiak, B.
Karasiewicz, M.
Kaminski, A.
Uzar, I.
Polaszewska, A.
Kostrzewa, Z.
Czerny, B.
Powiązania:
https://bibliotekanauki.pl/articles/72469.pdf
Data publikacji:
2018
Wydawca:
Instytut Włókien Naturalnych i Roślin Zielarskich
Tematy:
gene expression
epigallocatechin-3-gallate
breast cancer
cancer cell
therapy
Opis:
Breast cancer is the most common malignant cancer among women. Both drug resistance and metastasis are major problems in the treatment of breast cancer. Therefore, adjuvant therapy may improve patients’ survival and affect their quality of life. It is suggested that epigallocatechin gallate (EGCG) which is well known for its chemopreventive activity and acts on numerous molecular targets may inhibit the growth and metastasis of some cancers. Hence, discovering the metastatic molecular mechanisms for breast cancer may be useful for therapy.The aim of the study was to determine the effect of EGGC on the mRNA expression level of genes such as ZEB1, ABCB1, MDM2, TWIST1 and PTEN in MCF-7 breast cancer cells. MCF7/DOX were cultured in the presence of 0.2 μM DOX and EGCG (20-50 μM). The mRNA expression level was determined by real-time quantitative PCR using RealTime ready Custom Panel 96 kit. Our results showed an important increase (about 2-fold for 20 μM EGCG + 0.2 μM DOX and 2.5-fold for 50 μM EGCG + 0.2 μM DOX, p<0.05) in ZEB1 expression levels. In case of ABCB1 gene lack of influence on the mRNA level was observed (p>0.05). We also observed significant decrease of ZEB1 expression in MCF7 cells with 20 μM and 50 μM EGCG (p<0.05). In addition, EGCG (20 μM) caused an increase of MDM2 and PTEN mRNA levels in almost 100% (p<0.05) and 40% (p>0.05), respectively. Lack of the influence of EGCG was noted for the TWIST1 gene expression. In case of MCF7/DOX we showed an increase of mRNA level of PTEN gene about 50% (p<0.05). These results suggest that EGCG may be potentially used in adjuvant therapy in the breast cancer treatment.
Źródło:
Herba Polonica; 2018, 64, 3
0018-0599
Pojawia się w:
Herba Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Wykorzystanie grafenu w medycynie : studium literaturowe
Use of graphene in medicine : the study of literature
Autorzy:
Bojko, Ł.
Ryniewicz, A. M.
Powiązania:
https://bibliotekanauki.pl/articles/135964.pdf
Data publikacji:
2015
Wydawca:
Wyższa Szkoła Techniczno-Ekonomiczna w Szczecinie
Tematy:
podawanie leków
podawanie genów
nanoplatformy
terapia nowotworów
skafoldy
drug delivery
gene delivery
nanoplatforms
cancer therapy
scaffolds
Opis:
Wstęp i cele: Wyizolowanie warstwy grafenu przez Andre Geim i Kostya Novoselov nastąpiło w 2004 roku. Ze względu na specyficzne właściwości elektryczne, optyczne, chemiczne i mechaniczne grafen znalazł zastosowanie w wielu dziedzinach, w tym w medycynie. Opracowanie poświęcone jest podsumowaniu najnowszych osiągnięć wykorzystania grafenu w procesie dostarczania leków, wykrywania i obrazowania struktur tkankowych, komórkowych i genowych, w tym terapii nowotworów oraz jako materiał w inżynierii tkankowej. Materiał i metody: Materiałem jest literatura dotycząca zagadnień zastosowania grafenu w medycynie. Zastosowano metodę analizy merytorycznej. Wyniki: Analiza literatury pokazuje, że przeszkodami dla biomedycznych zastosowań nanomateriałów na bazie grafenu jest brak biodegradacji i możliwość wystąpienia toksyczności długoterminowej, a obecne badania nie dostarczają pełnej wiedzy w zakresie oddziaływania in vivo nanomateriałów na bazie grafenu, o różnej strukturze, wielkości i właściwości powierzchni. Wniosek: Efektywność kierowania markerów do guzów nowotworowych jest jednym z kluczowych wyzwań biomedycznych dotyczących nie tylko materiałów na bazie grafenu, ale także większości innych nanomateriałów.
Introduction and aims: The isolation of graphene layers by Andre Geim and Kostya Novoselov was in 2004. Due to the specific properties of the electrical, optical, chemical and mechanical properties, graphene has been applied in many fields, including medicine. Study is devoted to the summary of the latest achievements in the use of graphene to drug delivery, sensing and imaging tissue, cellular, and gene structures, including cancer therapy and as a material for tissue engineering. Material and methods: The material is literature on the issues of application of graphene in medicine. The method of theoretical analysis. Results: Analysis of the literature shows that obstacles to biomedical applications of nanomaterials based on graphene is the lack of biodegradability and the possibility of long-term toxicity and current research does not provide the full knowledge of the interactions in vivo graphene-based nanomaterials, with a different structure, size and surface properties. Conclusion: Efficiency of targeting cancerous tumors markers is one of the key challenges regarding not only the biomedical materials based on graphene, but also most other nanomaterials.
Źródło:
Problemy Nauk Stosowanych; 2015, 3; 147-156
2300-6110
Pojawia się w:
Problemy Nauk Stosowanych
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Direct transfer of IL-12 gene into growing Renca tumors.
Autorzy:
Budryk, Magdalena
Wilczyńska, Urszula
Szary, Jarosław
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1044365.pdf
Data publikacji:
2000
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
IL-12 gene
tumor gene therapy
naked DNA
Opis:
We investigated the feasibility of transferring naked plasmid DNA containing a therapeutic gene (IL-12) into mice harboring growing Renca tumors. We found that naked DNA transferred into growing Renca and B16(F10) tumors gives higher expression level of reporter gene than complexes of DNA with DDAB/ DOPE or DC-Chol/DOPE. Transfer of naked DNA carrying the IL-12 gene into growing Renca tumors causes a distinct therapeutic effect that depends on the time span between inoculation of mice with cancer cells and the beginning of the therapy. Therapy started on day 3 resulted in total cure (100%) of mice.
Źródło:
Acta Biochimica Polonica; 2000, 47, 2; 385-391
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter.
Autorzy:
Dąbrowska, Anna
Szary, Jarosław
Kowalczuk, Małgorzata
Szala, Stanisław
Ugorski, Maciej
Powiązania:
https://bibliotekanauki.pl/articles/1041550.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
CEA promoter
E. coli cytosine deaminase
gene-directed enzyme prodrug therapy
Opis:
Recent studies have suggested that carcinoembryonic antigen (CEA)-promoter sequences are active only in CEA-positive cells, filing in the criteria for tumor specific targeting of suicide genes. However, the present study on gene therapy of colon cancer and cell-specificity of CEA promoter, provide evidence that CEA-positive and CEA-negative cells transfected with E. coli cytosine deaminase (CD) gene under the control of CEA promotor sequence are sensitive to enzyme/pro-drug therapy with 5-fluorocytosine (5-FC). Individual clones derived from the CEA-negative cell lines: melanoma Hs294T and glioblastoma T98G after transfection with CD differed profoundly in their sensitivity to 5-FC. The IC50 values for several clones of the CEA-negative cells were almost the same as for CEA-positive colon cancer cells. Such 5-FC-sensitive clones derived from the population of CEA-negative cells, present even in small number, because of the very effective bystender effect of this enzyme/pro-drug system can cause severe problems during therapy by efficiently killing surrounding normal cells. Safety is the major issue in gene therapy. Our data suggest that the safety of gene-directed enzyme pro-drug therapy (GDEPT) with CEA promoter driven expression of therapeutic genes is not so obvious as it has originally been claimed.
Źródło:
Acta Biochimica Polonica; 2004, 51, 3; 723-732
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Charakterystyka nanostrukturalna materiału genetycznego do zastosowania w terapii genowej
Nanostructural characteristics of genetic material for gene therapy application
Autorzy:
Duda, M.
Frączkowska, K.
Przybyło, M.
Kopaczyńska, M.
Powiązania:
https://bibliotekanauki.pl/articles/261139.pdf
Data publikacji:
2015
Wydawca:
Politechnika Wrocławska. Wydział Podstawowych Problemów Techniki. Katedra Inżynierii Biomedycznej
Tematy:
kondensacja DNA
spermidyna
terapia genowa
mikroskopia sił atomowych
DNA condensation
spermidine
gene therapy
atomic force microscopy (AFM)
Opis:
Terapia genowa jest obecnie bardzo dynamicznie rozwijającą się techniką biomedyczną, która może znaleźć zastosowanie w medycynie w leczeniu chorób przewlekłych i dziedzicznych. Badania skupiają się na opracowywaniu nowych strategii dotyczących procesów kondensacji i ochrony materiału genetycznego (DNA) wprowadzanego do komórki docelowej. Struktura i stopień upakowania dostarczanego DNA wpływają na kluczowe właściwości fizykochemiczne, determinujące czy wprowadzony wektor rekombinowany ulegnie ekspresji, czy też degradacji. Związki chemiczne, zwane czynnikami kondensującymi, to substancje powodujące zwinięcie DNA, a stopień kondensacji materiału genetycznego zależy bezpośrednio od rodzaju i stężenia użytego czynnika kondensującego. Do cząsteczek wykazujących właściwości kondensujące należą poliaminy, w opisywanym eksperymencie zastosowano poliaminę – spermidynę. Przeprowadzone badania miały na celu charakterystykę nanostrukturalną materiału genetycznego pod wpływem działania czynnika kondensującego. W wyniku analizy wykonanej za pomocą mikroskopii sił atomowych (AFM) wykazano, że plazmid DNA ulega kondensacji pod wpływem spermidyny, formując struktury rozetowe.
Gene therapy is a new promising method that may find many applications in modern biomedicine. Especially, it may be a powerful tool in chronic and hereditary diseases treatment. Current studies focus on development of novel strategies concerning genetic material (DNA) condensation and protection, whilst it is introduced into the cellular nucleus. Once the DNA enters the cell, it’s either passed on and expressed in the nucleus or degraded by intracellular nucleases. The structure and the degree of compaction influence physicochemical properties that determine what will happen to delivered genetic material. DNA coiling can be caused by chemical compounds called compaction agents, such as polyamines like spermidine used in this study. The aim of this research was to examine the nanostructural characteristics of genetic material exposed to compaction agent. The measurements and analysis performed by atomic force microscopy (AFM) indicate that DNA plasmid undergoes condensation and forms rosette-like structures once subjected to spermidine.
Źródło:
Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna; 2015, 21, 1; 1-8
1234-5563
Pojawia się w:
Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Stem cells: applications, perspectives, misunderstandings
Autorzy:
Dulak, Józef
Powiązania:
https://bibliotekanauki.pl/articles/704245.pdf
Data publikacji:
2020
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
stem cells
cellular therapies
gene therapy
embryonic stem cells
induced pluripotent stem cells
Opis:
Stem cells exist and can do a lot. For several decades, bone marrow and umbilical cord blood transplants containing haematopoietic stem cells have been used in the treatment of blood diseases. Genetic modifications (gene therapy) of such cells help to cure complex immunodeficiencies and severe anaemias. The limbal stem cells taken from the eye and properly multiplied can regenerate the damaged cornea, and the epidermal stem cells help in the treatment of severe burns and some hereditary, severe skin diseases. Promising experimental research is under way on other uses of stem cells. However, these cells are appropriately selected, having real ability to differentiate into specialized cells whose malfunction is the cause of the disease. Therapeutic applications of stem cells are apparently limited to date. Meanwhile, the Internet is full of advertisements for supposedly miraculous treatments for almost any disease. Stem cells have become a modern synonym of the Holy Grail. A wonderful dish, transforming every drink into elixir of health, youth and long life. Stem cells from a single source, e.g., umbilical cord blood, or so-called cells, although without proven properties of stem cells, are offered in commercial private clinics as a panacea for autism, cerebral palsy, spina bifida, eye diseases, amyotrophic lateral sclerosis and dozens other disorders. Without justification for their action in these diseases, without convincing evidence of safety, but for a high fee. This article discusses stem cells and misunderstandings about including any cells among them. It draws attention to the real possibilities and confirmed uses of stem cells and presents the problems, doubts and dangers for patients associated with commercial offers of treatments using “stem” cells. The author cites the positions of scientific institutions and societies warning against premature commercialization of unjustified and potentially dangerous therapies
Źródło:
Nauka; 2020, 1
1231-8515
Pojawia się w:
Nauka
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Newest therapeutic options for adrenoleukodystrophy
Autorzy:
Gołębiowska, Maria
Gołębiowska, Beata
Beń-Skowronek, Iwona
Powiązania:
https://bibliotekanauki.pl/articles/1163988.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
X-ALD
adrenoleukodystrophy
gene therapy
neurodegenerative disorders
Opis:
X-linked adrenoleukodystrophy is a genetic disease correlated with mutation of ATP-binding cassette, which results in errors of peroxisomal beta oxidation and accumulation of impaired very long chain fatty acids. This leads to degeneration of adrenal glands, spinal cord and myelin sheaths. Despite nearly 100 years of ALD history, the treatment is limited to few therapeutic options, mainly Lorenzo’s Oil and Hematopoetic stem cell transplant. Available therapy can only slow the progression of the disease in early stages. The aim of our study was to present the newest therapeutic options in X-ALD. Substantial articles on new treatment of X-ALD from period 2007-2018 in the Asian, European and American regions have been analyzed. Among 219 articles in PubMed Medline database related to therapy and treatment of X-ALD, 13 articles were selected for analysis, reviewed and divided into two main groups: cause-related treatment (11 articles) and symptoms-related treatment (2 articles). Within cause-related treatment, the usage of known medications such as eg. pioglitazone, natural phenols - resveratrol, gene therapy with adenoassociated virus serotype 9 or combined therapies (Hematopoetic Stem Cell Gene Therapy) have been reviewed. Symptoms related treatment attempted to reduce spasticity and secondary dystonia in X-ALD patients. Reviewed research presents progress in development of treatment options for X-ALD, however still in primary in vitro and animal tested stages. Secondary neurological symptoms medication is awaiting for better solutions for ALD patients, in order to improve their Quality of Life and allow symptomless course for a longer time.
Źródło:
World Scientific News; 2018, 108; 133-143
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
Autorzy:
Jazowiecka-Rakus, Joanna
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1041570.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cancer gene therapy
tumour targeting
cytosine deaminase
Salmonella
Opis:
A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 × 106 cfu/g and decreased in tumours down to 5.9 × 106 cfu/g. VNP20047 at 1 × 105 cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.
Źródło:
Acta Biochimica Polonica; 2004, 51, 3; 851-856
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours
Autorzy:
Jazowiecka-Rakus, Joanna
Jarosz, Magdalena
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1041289.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
combination
vasostatin
cyclophosphamide
gene therapy
Opis:
Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.
Źródło:
Acta Biochimica Polonica; 2006, 53, 1; 199-202
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Helper-dependent adenoviral vectors in experimental gene therapy
Autorzy:
Józkowicz, Alicja
Dulak, Józef
Powiązania:
https://bibliotekanauki.pl/articles/1041362.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
helper-dependent adenoviral vectors
adenoviruses
gene therapy
Opis:
In the majority of potential applications gene therapy will require an effective transfer of a transgene in vivo resulting in high-level and long-term transgene expression, all in the absence of significant toxicity or inflammatory responses. The most efficient vehicles for delivery of foreign genes to the target tissues are modified adenoviruses. Adenoviral vectors of the first generation, despite the high infection efficacy, have an essential drawback: they induce strong immune response, which leads to short term expression of the transgene, and limits their usefulness in clinical trials. In contrast, helper-dependent adenoviral vectors (HdAd) lacking all viral coding sequences display only minimal immunogenicity and negligible side-effects, allowing for long-term transgene expression. Thus, HdAd vehicles have become the carrier of choice for adenoviral vector-mediated experimental gene therapy, effectively used in animal models for delivery of transgenes into the liver, skeletal muscle, myocardium or brain. Strong and long-lasting expression of therapeutic genes has allowed for successful treatment of dyslipidemias, muscular dystrophy, obesity, hemophilia, and diabetes. Additionally, the large cloning capacity of HdAd, up to 37 kb, facilitates the use of physiologically regulated, endogenous promoters, instead of artificial viral promoter sequences. This enables also generation of the single vectors expressing multiple genes, which can be potentially useful for treatment of polygenic diseases. In this review we characterize the basic features of HdAd vectors and describe some of their experimental and potential clinical applications.
Źródło:
Acta Biochimica Polonica; 2005, 52, 3; 589-599
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Adeno-associated virus vector-mediated gene delivery to the vasculature and kidney.
Autorzy:
Kapturczak, Matthias
Chen, Sifeng
Agarwal, Anupam
Powiązania:
https://bibliotekanauki.pl/articles/1041403.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
kidney
vasculature
viral vectors
endothelium
recombinant adeno-associated virus
gene therapy
Opis:
Relatively successful elsewhere, gene delivery aimed at the vasculature and kidney has made very little progress. In the kidney, the hurdles are related to the unique structure–function relationships of this organ and in the blood vessels to a variety of, mostly endothelial, factors making the delivery of transgenes very difficult. Among gene-therapeutic approaches, most viral gene delivery systems utilized to date have shown significant practical and safety-related limitations due to the level and duration of recombinant transgene expression as well as their induction of a significant host immune response to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term transgene expression. rAAV-based vectors are characterized by a relative non-immunogenicity and the absence of viral coding sequences. Furthermore, they allow for establishment of long-term latency without deleterious effects on the host cell. This brief review addresses problems related to transgene-delivery to kidney and vasculature with particular attention given to rAAV vectors. The potential for gene therapy as a strategy for selected renal and vascular diseases is also discussed.
Źródło:
Acta Biochimica Polonica; 2005, 52, 2; 293-299
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cancer immunotherapy using cells modified with cytokine genes.
Autorzy:
Kowalczyk, Dariusz
Wysocki, Piotr
Mackiewicz, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/1043434.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cancer
cancer vaccines
cytokines
dendritic cells
gene therapy
Opis:
The ability of various cytokines to hamper tumor growth or to induce anti-tumor immune response has resulted in their study as antitumor agents in gene therapy approaches. In this review we will concentrate on the costimulation of antitumor immune responses using modification of various cell types by cytokine genes. Several strategies have emerged such as (i) modification of tumor cells with cytokine genes ex vivo (whole tumor cell vaccines), (ii) ex vivo modification of other cell types for cytokine gene delivery, (iii) delivery of cytokine genes into tumor microenvironment in vivo, (iv) modification of dendritic cells with cytokine genes ex vivo. Originally single cytokine genes were used. Subsequently, multiple cytokine genes were applied simultaneously, or in combination with other factors such as chemokines, membrane bound co-stimulatory molecules, or tumor associated antigens. In this review we discuss these strategies and their use in cancer treatment as well as the promises and limitations of cytokine based cancer gene therapy. Clinical trials, including our own experience, employing the above strategies are discussed.
Źródło:
Acta Biochimica Polonica; 2003, 50, 3; 613-624
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
DNA microarrays - future in oncology research and therapy
Autorzy:
Krol, M.
Pawlowski, K.M.
Otrebska, D.
Motyl, T.
Powiązania:
https://bibliotekanauki.pl/articles/3349.pdf
Data publikacji:
2008
Wydawca:
Instytut Medycyny Wsi
Tematy:
DNA microarray
future
oncology
research
therapy
genomics
gene expression
canine mammary cancer
tumour
human disease
cancer
Źródło:
Journal of Pre-Clinical and Clinical Research; 2008, 02, 2
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo.
Autorzy:
Małecki;, Maciej
Przybyszewska, Małgorzata
Janik, Przemysław
Powiązania:
https://bibliotekanauki.pl/articles/1043468.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
gene therapy
bicistronic vectors
Opis:
Manipulation of angiogenesis in vivo is an example of successful gene therapy strategies. Overexpression of angiogenic genes like VEGF, FGF or PDGF causes new vessel formation and improves the clinical state of patients. Gene therapy is a very promising procedure but requires large amounts of pharmaceutical-grade plasmid DNA. In this regard we have constructed a bicistronic plasmid DNA vector encoding two proangiogenic factors, VEGF165 and FGF-2. The construct (pVIF) contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) which permits both genes to be translated from a single bicistronic mRNA. The IRES sequence allows for a high efficiency of gene expression in vivo. The pVIF vector was characterized in vitro and in vivo. In vivo angiogenesis studies showed that the bicistronic vector encoding two proangiogenic factors induces the formation of new vessels significantly more than pVEGF165 or pFGF-2 alone. In our opinion the combined proangiogenic approach with VEGF165 and FGF-2 is more powerful and efficient than single gene therapy. We also postulate that IRES sequence can serve as a useful device improving efficiency of gene therapy.
Źródło:
Acta Biochimica Polonica; 2003, 50, 3; 875-882
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 32

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies